---
title: "Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer: Clinical trials questions"
description: "Clinical trials questions on Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results. Questions: How was the DATROWAY TROPION-Breast01 trial designed? How long does DATROWAY delay breast cancer progression compared with chemotherapy (TROPION-Breast01)? Do patients live longer on DATROWAY than on chemotherapy (TROPION-Breast01)? What was the DATROWAY response rate in TROPION-Breast01? 1 further question follow. 5 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/clinical-trials"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer: Clinical trials questions

Manufacturer: Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP  
Prescribing information: [Datroway](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Datroway&inline=true)

## Clinical trials

<a id="datroway-breast01-design"></a>

### How was the DATROWAY TROPION-Breast01 trial designed?

> “TROPION-Breast01: A multicenter, open-label, randomized phase 3 trial of DATROWAY (6 mg/kg IV Q3W; n=365) vs investigator’s choice of chemotherapy (eribulin, capecitabine, vinorelbine, or gemcitabine; n=367) in 732 previously treated patients with unresectable or metastatic HR+/HER2− breast cancer. Patients must have progressed on and deemed not suitable for further endocrine therapy, and received 1 or 2 lines of prior chemotherapy in the unresectable or metastatic disease setting. Stratification factors included 1 or 2 previous lines of chemotherapy, prior CDK4/6 inhibitor use, and geography. Dual primary endpoints were PFS (BICR) and OS.<sup>1,2</sup>”

Source: [DATROWAY: DATROWAY® (datopotamab deruxtecan-dlnk) | HR+/HER2– mBC, captured 2026-11-08](https://datrowayhcp.com/hr-positive-her2-negative-mbc#:~:text=TROPION%2DBreast01%3A%20A%20multicenter%2C%20open%2Dlabel%2C%20randomized,endpoints%20were%20PFS%20%28BICR%29%20and)

> “No prior ADC use was permitted.<sup>2</sup>”

Source: [DATROWAY: TROPION-Breast01 Trial, captured 2026-11-08](https://datrowayhcp.com/hr-positive-her2-negative-mbc/study-design#:~:text=No%20prior%20ADC%20use%20was)

## Study results

<a id="datroway-pfs-results"></a>

### How long does DATROWAY delay breast cancer progression compared with chemotherapy (TROPION-Breast01)?

> “Superior
> mPFS<sup>1†</sup>
>
> 6.9 months with
> DATROWAY
> (n=365)
>
> VS
>
> 4.9 months with
> chemotherapy
> (n=367)
>
> (HR=0.63; 95% CI: 0.52, 0.76; P<0.0001)
>
> Median OS (dual primary endpoint): 18.6 months with DATROWAY and 18.3 months with chemotherapy (HR=1.01; 95% CI: 0.83, 1.22). Data was not statistically significant.<sup>1</sup>”

Source: [DATROWAY: DATROWAY® (datopotamab deruxtecan-dlnk) | HR+/HER2– mBC, captured 2026-11-08](https://datrowayhcp.com/hr-positive-her2-negative-mbc#:~:text=6.9%20months%20with,1.22%29.%20Data%20was%20not%20statistically)

> “TROPION-Breast01 had dual primary endpoints of PFS (BICR) and OS (see below for summary of study design). The study was positive if either PFS or OS results were statistically significant.<sup>1,7</sup>”

Source: [DATROWAY: DATROWAY® (datopotamab deruxtecan-dlnk) | HR+/HER2– mBC, captured 2026-11-08](https://datrowayhcp.com/hr-positive-her2-negative-mbc#:~:text=TROPION%2DBreast01%20had%20dual%20primary%20endpoints,or%20OS%20results%20were%20statistically)

<a id="datroway-overall-survival"></a>

### Do patients live longer on DATROWAY than on chemotherapy (TROPION-Breast01)?

> “Median overall survival<sup>1</sup>
>
> 18.6 months with DATROWAY and
> 18.3 months with chemotherapy
>
> HR=1.01 (95% CI: 0.83, 1.22). Data was not statistically significant.”

Source: [DATROWAY: Efficacy Results from TROPION-Breast01, captured 2026-11-08](https://datrowayhcp.com/hr-positive-her2-negative-mbc/efficacy#:~:text=Median%20overall,Data%20was%20not%20statistically%20significant.)

<a id="datroway-response-rate"></a>

### What was the DATROWAY response rate in TROPION-Breast01?

> “The major efficacy outcomes were progression-free survival (PFS) as assessed by blinded independent central review 
> (BICR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 and overall survival (OS). Additional 
> efficacy outcomes included confirmed objective response rate (ORR) and duration of response (DOR) by BICR.”

Source: [DATROWAY: Prescribing information, page 22, captured 2026-11-08](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Datroway&inline=true#page=22)

> “Table 13: Efficacy Results in TROPION-Breast01 
> DATROWAY 
> (n=365) 
> Chemotherapy 
> (n=367) 
>
> Progression-Free Survival <sup>a</sup>  
>   Number of events (%) 
> 212 (58) 
> 235 (64) 
>      Progressive Disease 
> 201 (55) 
> 218 (59) 
>      Death 
> 11 (3) 
> 17 (5) 
>   Median, months (95% CI) 
> 6.9 (5.7, 7.4) 
> 4.9 (4.2, 5.5) 
>   Hazard ratio (95% CI) <sup>b</sup> 
> 0.63 (0.52, 0.76) 
>   p-value <sup>c, d</sup> 
> < 0.0001 
> Overall Survival 
>   Number of events (%) 
> 223 (61) 
> 213 (58) 
>   Median, months (95% CI) 
> 18.6 (17.3, 20.1) 
> 18.3 (17.3, 20.5) 
>   Hazard ratio (95% CI) <sup>b</sup> 
> 1.01 (0.83, 1.22) 
>   p-value <sup>c</sup> 
> NS 
> Confirmed Objective Response Rate <sup>a</sup> 
>   n (%) 
> 133 (36) 
> 84 (23) 
>  (95% CI) 
> 31, 42 
> 19, 28”

Source: [DATROWAY: Prescribing information, page 22, captured 2026-11-08](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Datroway&inline=true#page=22)

<a id="datroway-landmark-pfs"></a>

### What percentage of DATROWAY patients had no progression at 9 and 12 months (TROPION-Breast01)?

> “Exploratory landmark data: The following analysis is descriptive only, as the trial was not powered to assess a statistical difference between treatment groups at these time points. Therefore, the clinical significance of these data is not known.<sup>2</sup>
>
> At 9 months, 38% of patients were progression free with DATROWAY and 19% with chemotherapy<sup>2</sup>
> At 12 months, 26% and 15% were progression free, respectively<sup>2</sup>”

Source: [DATROWAY: Efficacy Results from TROPION-Breast01, captured 2026-11-08](https://datrowayhcp.com/hr-positive-her2-negative-mbc/efficacy#:~:text=Exploratory%20landmark%20data%3A%20The%20following,and%2015%25%20were%20progression%20free%2C)

## Related pages
- [Medical information: Datroway (datopotamab deruxtecan-dlnk): HR-positive HER2-negative breast cancer](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/access-and-coverage)
